Mylan Institutional is recalling an injectable medication used by cancer patients due to foreign particulate matter discovered during stability testing.
The recall involves two lots of Levoleucovorin injection 250 mg/25 mL with lot numbers APB032 and APB033. Both lots have an expiration date of April 2019.
The recall covers wholesalers, retailers and consumers.
Injection of foreign particulates can cause severe health problems, including allergic reactions and pulmonary embolism, Mylan said. In this case, the foreign matter was identified as copper salts.
Mylan said that to date, it had not received any reports of adverse events related to this recall.
The medication was manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan.
Consumers with questions should call Mylan customer relations at 800-796-9526. To receive a documentation packet to return the product, contact Stericycle at 866-551-2706.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.
The medication is used by cancer patients. The recall — which covers wholesalers, retailers and consumers — involves lots APB032 and APB033. Both lots have an expiration date of April 2019. The medication was manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan. Injection of foreign particulates can cause severe health problems, including allergic reactions and pulmonary embolism, Mylan said. Consumers with questions should contact Stericycle at 866-551-2706.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.